Cargando…

Prevalence of group A streptococcal disease in North and Sub-Saharan Africa: a systematic review protocol

INTRODUCTION: The true burden of group A streptococcal (GAS) disease in Africa is not known. GAS is a significant cause of mortality and morbidity on the global scale and in developing countries. According to Carapetis et al, the prevalence of severe GAS disease is at least 18.1 million cases with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Barth, Dylan D, Mayosi, Bongani M, Jabar, Ardil, Engel, Mark E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554900/
https://www.ncbi.nlm.nih.gov/pubmed/26316653
http://dx.doi.org/10.1136/bmjopen-2015-008646
_version_ 1782388099121152000
author Barth, Dylan D
Mayosi, Bongani M
Jabar, Ardil
Engel, Mark E
author_facet Barth, Dylan D
Mayosi, Bongani M
Jabar, Ardil
Engel, Mark E
author_sort Barth, Dylan D
collection PubMed
description INTRODUCTION: The true burden of group A streptococcal (GAS) disease in Africa is not known. GAS is a significant cause of mortality and morbidity on the global scale and in developing countries. According to Carapetis et al, the prevalence of severe GAS disease is at least 18.1 million cases with an incidence of at least 1.78 million cases per year. METHODS AND ANALYSES: We aim to provide a systematic review of studies measuring the prevalence of GAS infection among people in North and Sub-Saharan African countries. A comprehensive literature search of a number of databases will be undertaken, using an African search filter, to identify GAS prevalence studies that have been published. Full copies of articles will be identified by a defined search strategy and will be considered for inclusion against predefined criteria. Statistical analysis will include two steps: (1) identification of data sources and documenting of estimates, and (2) the application of the random-effects and fixed-effects meta-analysis model to aggregate prevalence estimates, and to account for between study variability in calculating the overall pooled estimates and 95% CI for GAS prevalence. Heterogeneity will be evaluated using the I(2) statistic to determine the extent of variation in effect estimates that is due to heterogeneity rather than chance. This systematic review protocol was prepared according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses Protocols (PRISMA-P) 2015 Statement. This review will provide updated evidence of a review published in 2009. Our data will have implications for the development of a GAS vaccine. ETHICS AND DISSEMINATION: Ethics approval is not required for this study given that this is a protocol for a systematic review of published studies. The results of this study will be disseminated through a peer-reviewed publication and conference presentation. SYSTEMATIC REVIEW REGISTRATION NUMBER: PROSPERO CRD4201401290 0. (http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014012900).
format Online
Article
Text
id pubmed-4554900
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45549002015-09-03 Prevalence of group A streptococcal disease in North and Sub-Saharan Africa: a systematic review protocol Barth, Dylan D Mayosi, Bongani M Jabar, Ardil Engel, Mark E BMJ Open Epidemiology INTRODUCTION: The true burden of group A streptococcal (GAS) disease in Africa is not known. GAS is a significant cause of mortality and morbidity on the global scale and in developing countries. According to Carapetis et al, the prevalence of severe GAS disease is at least 18.1 million cases with an incidence of at least 1.78 million cases per year. METHODS AND ANALYSES: We aim to provide a systematic review of studies measuring the prevalence of GAS infection among people in North and Sub-Saharan African countries. A comprehensive literature search of a number of databases will be undertaken, using an African search filter, to identify GAS prevalence studies that have been published. Full copies of articles will be identified by a defined search strategy and will be considered for inclusion against predefined criteria. Statistical analysis will include two steps: (1) identification of data sources and documenting of estimates, and (2) the application of the random-effects and fixed-effects meta-analysis model to aggregate prevalence estimates, and to account for between study variability in calculating the overall pooled estimates and 95% CI for GAS prevalence. Heterogeneity will be evaluated using the I(2) statistic to determine the extent of variation in effect estimates that is due to heterogeneity rather than chance. This systematic review protocol was prepared according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses Protocols (PRISMA-P) 2015 Statement. This review will provide updated evidence of a review published in 2009. Our data will have implications for the development of a GAS vaccine. ETHICS AND DISSEMINATION: Ethics approval is not required for this study given that this is a protocol for a systematic review of published studies. The results of this study will be disseminated through a peer-reviewed publication and conference presentation. SYSTEMATIC REVIEW REGISTRATION NUMBER: PROSPERO CRD4201401290 0. (http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014012900). BMJ Publishing Group 2015-08-27 /pmc/articles/PMC4554900/ /pubmed/26316653 http://dx.doi.org/10.1136/bmjopen-2015-008646 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Epidemiology
Barth, Dylan D
Mayosi, Bongani M
Jabar, Ardil
Engel, Mark E
Prevalence of group A streptococcal disease in North and Sub-Saharan Africa: a systematic review protocol
title Prevalence of group A streptococcal disease in North and Sub-Saharan Africa: a systematic review protocol
title_full Prevalence of group A streptococcal disease in North and Sub-Saharan Africa: a systematic review protocol
title_fullStr Prevalence of group A streptococcal disease in North and Sub-Saharan Africa: a systematic review protocol
title_full_unstemmed Prevalence of group A streptococcal disease in North and Sub-Saharan Africa: a systematic review protocol
title_short Prevalence of group A streptococcal disease in North and Sub-Saharan Africa: a systematic review protocol
title_sort prevalence of group a streptococcal disease in north and sub-saharan africa: a systematic review protocol
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554900/
https://www.ncbi.nlm.nih.gov/pubmed/26316653
http://dx.doi.org/10.1136/bmjopen-2015-008646
work_keys_str_mv AT barthdyland prevalenceofgroupastreptococcaldiseaseinnorthandsubsaharanafricaasystematicreviewprotocol
AT mayosibonganim prevalenceofgroupastreptococcaldiseaseinnorthandsubsaharanafricaasystematicreviewprotocol
AT jabarardil prevalenceofgroupastreptococcaldiseaseinnorthandsubsaharanafricaasystematicreviewprotocol
AT engelmarke prevalenceofgroupastreptococcaldiseaseinnorthandsubsaharanafricaasystematicreviewprotocol